

The Medical Letter[®]

on Drugs and Therapeutics

Volume 68

January 5, 2026

ISSUE No.
1745

IN THIS ISSUE

In Brief: Alternatives to *Bicillin L-A*.....p 7

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 68 (Issue 1745)

January 5, 2026

Take CME Exams

IN BRIEF

Alternatives to *Bicillin L-A*

In July 2025, Pfizer issued a voluntary recall of certain lots of long-acting intramuscular (IM) benzathine penicillin G (*Bicillin L-A*) due to particulates identified during visual inspection.¹ The CDC issued a "Dear Colleague Letter" to alert healthcare providers about the recall and provide advice on how to manage the potentially limited supply of the drug for treatment of syphilis, which has been increasing in the US.² Benzathine penicillin G is also used for treatment of group A streptococcal pharyngitis and prophylaxis of rheumatic fever.

In response to a previous shortage of *Bicillin L-A* in 2023, the FDA approved temporary importation of two equivalent IM penicillin formulations, *Extencilline* (benzathine benzylpenicillin) and *Lentocilin S* (benzathine benzylpenicillin tetrahydrate), both of which remain available (see Table 1).

Table 1. Benzathine Penicillin G/Benzathine Benzylpenicillin Formulations

Brand Name	Formulations	Cost ¹
<i>Bicillin L-A</i> (Pfizer)	600,000 units/mL, 1.2 MU/2 mL, 2.4 MU/4 mL prefilled syringes ²	\$369.00
<i>Extencilline</i> (Laboratories Delbert) ^{3,4}	1.2 MU/5 mL, 2.4 MU/7 mL vials ⁵	190.00
<i>Lentocilin S</i> (Laboratorios Atral) ^{3,6}	1.2 MU/4 mL vials ⁵	14.60

MU = million units

1. Approximate WAC for 1 syringe or vial containing 1.2 MU. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. December 5, 2025. Reprinted with permission by First Databank, Inc. All rights reserved. ©2025. www.fdbhealth.com/policies/drug-pricing-policy.
2. The 1.2 and 2.4 MU syringes are on intermittent backorder with weekly releases. 600,000-unit syringes are on backorder; the manufacturer estimated a release date of December 2025. Status of 1.2 and 2.4 MU syringes is available at pfizerhospitalus.com.
3. Non-FDA-approved drug imported temporarily.
4. Imported to the US by Provepharm. Contains soy phospholipids.
5. Supplied as powder and diluent for reconstitution.
6. Imported to the US by Mark Cuban Cost Plus Drug Company.

SYPHILIS – IM benzathine penicillin G is the drug of choice for treatment of primary, secondary, or early latent syphilis (<1 year's duration) and for late latent (>1 year's duration), latent of unknown duration,

Table 2. Treatment of Syphilis¹

Regimen of Choice	Alternatives
Primary, Secondary, or Early Latent (<1 Year)	
Benzathine penicillin G ² 2.4 MU IM once	Doxycycline 100 mg PO bid x 14 days ^{3,4} Tetracycline 500 mg PO qid x 14 days ^{3,4} Ceftriaxone 1 g IV or IM once/day x 10 days ⁴
Late Latent, Latent of Unknown Duration, or Tertiary	
Benzathine penicillin G ² 2.4 MU IM once/week x 3 weeks	Doxycycline 100 mg PO bid x 14 days ^{3,4} Tetracycline 500 mg PO qid x 14 days ^{3,4}

MU = million units

1. Adapted from KA Workowski et al. MMWR Recomm Rep 2021; 70:1
2. The only drug with documented efficacy in pregnant women with syphilis. If allergic to penicillin, skin tests, desensitization, and treatment with penicillin G are recommended.
3. Not recommended for use during pregnancy or breastfeeding.
4. Efficacy not established; generally used only when patient is allergic to penicillin. Adherence must be ensured.

or tertiary syphilis (gumma or cardiovascular).³ Doxycycline is usually recommended as an alternative when benzathine penicillin G cannot be given. Tetracycline is another alternative, but it causes more gastrointestinal adverse effects and requires more frequent dosing. Ceftriaxone appears to be effective for primary and secondary syphilis, but data are limited (see Table 2).⁴

Because parenteral penicillin G is the only drug with documented efficacy for treatment of syphilis during pregnancy, the CDC recommends considering use of doxycycline to treat syphilis in men and nonpregnant women during the supply shortage.² Pregnant women with syphilis who are allergic to penicillin should be desensitized and treated with penicillin G.⁴

ANTISTREPTOCOCCAL PROPHYLAXIS – Long-term antimicrobial prophylaxis is recommended for prevention of recurrent episodes of streptococcal pharyngitis and acute rheumatic fever, which can worsen the severity of rheumatic heart disease. IM benzathine penicillin G once every 28 days is the drug of choice for prophylaxis. Twice-daily administration of oral penicillin V is an alternative that is commonly used in nonendemic areas such as the US, but the risk of recurrence is higher with oral prophylaxis.⁵ Oral azithromycin or sulfadiazine can be used in patients with a confirmed allergy to penicillin. ■

1. Pfizer. Urgent: drug recall. Bicillin L-A. July 10, 2025. Available at: <https://bit.ly/46Jt8od>. Accessed December 15, 2025.
2. CDC. Bicillin L-A. Priority actions following recall. July 18, 2025. Available at: <https://bit.ly/45taFdq>. Accessed December 15, 2025.
3. Drugs for sexually transmitted infections. *Med Lett Drugs Ther* 2022; 64:97.
4. KA Workowski et al. Sexually transmitted infections treatment guidelines, 2021. *MMWR Recomm Rep* 2021; 70:1.
5. MA Gerber et al. Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. *Circulation* 2009; 119:1541.

PRESIDENT, EDITOR IN CHIEF: Jean-Marie Pflomm, Pharm.D.; **EDITOR IN CHIEF EMERITUS:** Mark Abramowicz, M.D.; **VICE PRESIDENT, ADMINISTRATION:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D.

CONSULTING EDITORS: Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Dartmouth Hitchcock Medical Center; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
2 Madison Ave, Ste 211
Larchmont, NY 10538
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):

1 year – \$179; \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints – \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.